Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Receivables (2023 - 2025)

Onconetix (ONCO) has disclosed Receivables for 2 consecutive years, with $461000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Receivables fell 55.84% to $461000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $461000.0, a 55.84% decrease, with the full-year FY2023 number at $308731.0, changed N/A from a year prior.
  • Receivables was $461000.0 for Q3 2024 at Onconetix, up from $55630.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.0 million in Q3 2023 to a low of $55630.0 in Q2 2024.